Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03488667 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 19, 2023 (before its estimated April 30, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Apr 30, 2023 to Apr 30, 2024 Trial status: Recruiting to Active, Not Recruiting · Completion date: Apr 30, 2023 to Apr 30, 2025 · Site details revisedv7 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Apr 30, 2023 to Apr 30, 2025
    • Site details revised
  2. Primary completion date: Apr 30, 2022 to Apr 30, 2023v6
  3. Primary completion date: Apr 30, 2020 to Apr 30, 2022 Completion date: Apr 30, 2021 to Apr 30, 2023v5 Show 1 more changeShow less
    • Completion date: Apr 30, 2021 to Apr 30, 2023
  4. Re-verified, no change to tracked fieldsv4
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 30, 2018 to Jun 27, 2018 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Apr 30, 2018 to Jun 27, 2018
    • Site details revised
  6. Secondary endpoints: details revised at 1 of 5 entries Eligibility criteria shortened, about 1 wordv2 Show 1 more changeShow less
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.
Trial Details
NCT Number NCT03488667
Lead Sponsor University of Kansas Medical Center
Collaborators: Merck Sharp & Dohme LLC
Conditions Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov